Affixing device and affixing device package

Abstract

An affixing device (1) has: a first base material sheet (11); a second base material sheet (12) disposed so as to overlap the first base material sheet (11), and having one end connected to the first base material sheet (11); a drug-containing resin layer (21) provided to the first base material sheet (11); a first release sheet (41) covering the drug-containing resin layer (21); a moisture retention part (31) provided to the second base material sheet (12) and disposed so as to overlap the drug-containing resin layer (21); a second release sheet (42) covering the moisture retention part (31); and a traction sheet (43) disposed between the first release sheet (41) and the second release sheet (42), having one end connected to the first release sheet (41) and the second release sheet (42), and having another end disposed so as not to overlap the first base material sheet (11), the second base material sheet (12), the first release sheet (41), and the second release sheet (42).

Description

Patch device and patch device package

[0001] The present disclosure relates to a patch device, and more specifically to a patch device used by being attached to the skin. The present disclosure also relates to a patch device package in which the patch device is enclosed in a packaging bag.

[0002] Conventionally, patch devices used by being attached to the skin are known. Patch devices are used for purposes such as medication administration, anesthesia, analgesia, anti-inflammation, and beauty care, for example. Since patch devices can transdermally deliver medicinal and active ingredients, they have the advantages of being non-invasive, imposing less burden on the user, and ensuring sustained administration.

[0003] As adhesive devices, for example, Patent Document 1 discloses a thermal cosmetic sheet, Patent Document 2 discloses a sheet-shaped face pack, Patent Document 3 discloses a gel sheet for packs, and Patent Document 4 discloses an adhesive patch. Specifically, Patent Document 1 discloses a package for a thermal cosmetic sheet in which a sheet-shaped heating element and a sheet-shaped cosmetic are separately contained, and the package has a fold line between the sheet-shaped heating element and the sheet-shaped cosmetic, and is arranged so that the sheet-shaped heating element and the sheet-shaped cosmetic overlap when folded in half along the fold line. Patent Document 2 discloses a sheet storage device having a first outer casing, a second outer casing, and a partition body disposed between them, the partition body dividing the interior into multiple regions, a sealing portion sealing the periphery of the first outer casing, the second outer casing, and the partition body, a plurality of sheets housed in each of the multiple regions, and cutting portions engraved on each of the first outer casing, the second outer casing, and the partition body. Patent Document 3 discloses a pack gel sheet packaging body having a tray consisting of a dish-shaped recess, a storage recess formed at the bottom of the tray for housing a pack gel sheet, and a liquid reservoir recess formed at the bottom of the storage recess for housing a beauty serum, the pack gel sheet packaging body packaging the pack gel sheet and the tray. Patent Document 4 discloses an adhesive patch comprising a support, an adhesive efficacy composition laminated on the surface of the support, and a sheet-like peel-off protective member peelably attached to the outer surface of the efficacy composition, wherein the peel-off protective member consists of a plurality of segmented peel-off pieces, the plurality of segmented peel-off pieces are separated and arranged adjacent to each other with a groove-shaped bending gap as the boundary, and the peel-off protective member is configured to be foldable with the bending gap as the crease.

[0004] Japanese Patent Publication No. 2010-053061, Japanese Patent Publication No. 2017-197269, Japanese Patent Publication No. 2006-056543, Japanese Patent Publication No. 2023-070505

[0005] When a patch device is applied to the skin, it is desirable that the penetration of the active ingredient or pharmacoactive component into the skin is ensured as much as possible, thereby enhancing the efficacy of the patch device. This disclosure aims to provide a patch device that can enhance the penetration of the drug from the drug-containing resin layer into the skin through simple operation. This disclosure also provides a patch device package in which the patch device according to this disclosure is enclosed in a packaging bag.

[0006] The adhesive device and adhesive device packaging according to the present disclosure that have been able to solve the aforementioned problems are as follows: [1] An adhesive device having a first direction and a second direction in the planar direction, comprising: a first base sheet; a second base sheet disposed on top of the first base sheet and having one end in the first direction or the second direction connected to the first base sheet; a drug-containing resin layer provided on the surface of the first base sheet facing the second base sheet; a first release sheet disposed on top of the surface of the first base sheet facing the second base sheet and covering the drug-containing resin layer; a moisture-retaining portion provided on the surface of the second base sheet facing the first base sheet and disposed on top of the drug-containing resin layer in a plan view of the adhesive device; and a second release sheet disposed on top of the surface of the second base sheet facing the first base sheet and covering the moisture-retaining portion. [1] An adhesive device comprising a traction sheet disposed between the first release sheet and the second release sheet, with a portion of the traction sheet overlapping the drug-containing resin layer and the moisture-retaining portion in the first direction, wherein one end in the first direction is connected to the first release sheet and the second release sheet, and the other end in the first direction is a traction sheet disposed without overlapping the first base sheet, the second base sheet, the first release sheet and the second release sheet. [2] The adhesive device according to [1], wherein the first base sheet and the second base sheet are formed on one side and the other side of the fold line, respectively, of one sheet folded back along a fold line. [3] The adhesive device according to [1] or [2], wherein the first release sheet and the second release sheet, the first release sheet and the traction sheet, or the second release sheet and the traction sheet are formed on one side and the other side of the fold line, respectively, of one sheet folded back along a fold line. [4] The adhesive device according to any one of [1] to [3], wherein the side of the drug-containing resin layer opposite to the first base sheet is adhesive. [5] The adhesive device according to any one of [1] to [4], wherein the side of the drug-containing resin layer opposite to the first base sheet has a hydrophobic region. [6] The adhesive device according to any one of [1] to [5], wherein the first base sheet and the second base sheet are separable.[7] The adhesive device according to any one of [1] to [6], wherein a support layer is provided on the first base sheet side of the drug-containing resin layer, and the support layer is peelably attached to the first base sheet. [8] The adhesive device according to [7], wherein the second base sheet has a temporary fixing portion of the drug-containing resin layer provided on at least a part of the periphery of the moisture-retaining portion. [9] The adhesive device according to any one of [1] to [8], wherein a recess is provided on the surface of the second base sheet facing the first base sheet, and the moisture-retaining portion is disposed in the recess.

[10] The adhesive device according to any one of [1] to [9], wherein the size of the drug-containing resin layer is smaller than the size of the moisture-retaining portion.

[11] The adhesive device according to any one of [1] to

[10] , wherein a recess is provided on the surface of the second base sheet facing the first base sheet, and the moisture-retaining portion and a temporary fixing portion of the drug-containing resin layer are provided in the recess, and the upper surface of the temporary fixing portion is located at a position lower than the upper surface of the moisture-retaining portion by 1 / 2 or less of the thickness of the moisture-retaining portion.

[12] The adhesive device according to any one of [1] to

[11] , wherein the first base sheet has a pressable portion formed therein that can be pressed into the second base sheet, and the drug-containing resin layer is disposed in the pressable portion.

[13] The adhesive device according to any one of [1] to

[12] , wherein the moisture-retaining portion has a porous body that retains moisture or a fiber aggregate that retains moisture.

[14] The adhesive device packaging comprising the adhesive device according to any one of [1] to

[13] and a packaging bag containing the adhesive device, wherein the packaging bag has an opening portion, and by opening from the opening portion, an outlet for the adhesive device is formed on the other end side of the traction sheet in the first direction.

[0007] The adhesive device according to this disclosure allows the first and second release sheets to be pulled out from between the first and second base sheets by pinching and pulling the other end of the traction sheet in the first direction. This brings the drug-containing resin layer into contact with the moisture-retaining portion, allowing moisture to adhere to the drug-containing resin layer. Subsequently, the overlap of the first and second base sheets is released, and the drug-containing resin layer is brought into contact with the skin, thus attaching the adhesive device to the skin. When the adhesive device is attached in this way, the moisture attached to the drug-containing resin layer adheres to the skin surface, softening and supple the skin surface with moisture. As a result, the adhesion of the drug-containing resin layer to the skin surface is increased, and the penetration of the drug from the drug-containing resin layer into the skin is enhanced. Furthermore, since moisture can be attached to the drug-containing resin layer with a simple operation, the adhesive device can be made easy to handle. The adhesive device packaging according to this disclosure makes it easy to grasp the other end of the traction sheet in the first direction when the packaging bag is opened, and by grasping and pulling the other end of the traction sheet in the first direction, moisture can be easily attached to the drug-containing resin layer.

[0008] Figure 1 shows an example of the configuration of the adhesive device according to this disclosure, and represents a plan view of the adhesive device. Figure 2 shows a cross-sectional view of the adhesive device shown along line II-II. Figure 3 shows a cross-sectional view of the adhesive device shown along line III-III. Figure 4 shows another example of the configuration of the adhesive device according to this disclosure, and represents a plan view of the adhesive device. Figure 4 shows a cross-sectional view of the adhesive device shown along line V-V. Figure 4 shows a cross-sectional view of the adhesive device shown along line VI-VI. Figure 4 shows a cross-sectional view of the adhesive device shown along line VI with the first release sheet, second release sheet, and traction sheet removed from the adhesive device shown along line 2. Figure 2 shows a cross-sectional view of a modified version of the adhesive device shown along line 2. Figure 3 shows another example of the configuration of the adhesive device according to this disclosure, and represents a cross-sectional view of the adhesive device. Figure 4 shows another example of the configuration of the adhesive device according to this disclosure, and represents a cross-sectional view of the adhesive device. Figure 5 shows another example of the configuration of the adhesive device according to this disclosure, and represents a cross-sectional view of the adhesive device. Figure 6 shows an example of the configuration of the adhesive device packaging according to this disclosure, and represents a plan view of the adhesive device packaging.

[0009] The contents of this disclosure will be described in detail below based on the embodiments described below. However, the contents of this disclosure are not limited by the embodiments described below, and it is certainly possible to implement the disclosure with appropriate modifications to the extent that it is in line with the spirit of the preceding and following descriptions, and all such modifications are included within the technical scope of this disclosure. In addition, hatching and component reference numerals may be omitted in the drawings for convenience, in which case refer to the specification or other drawings. Furthermore, the dimensions of various components in the drawings may differ from the actual dimensions, as priority is given to helping to understand the features of this disclosure.

[0010] An example of the configuration of an adhesive device according to an embodiment of the present disclosure will be described with reference to Figures 1 to 8. Figures 1 to 3 show an adhesive device according to the first embodiment, where Figure 1 is a plan view of the adhesive device, Figure 2 is a cross-sectional view taken along line II-II of the adhesive device shown in Figure 1, and Figure 3 is a cross-sectional view taken along line III-III of the adhesive device shown in Figure 1. Figures 4 to 6 show an adhesive device according to the second embodiment, where Figure 4 is a plan view of the adhesive device, Figure 5 is a cross-sectional view taken along line V-V of the adhesive device shown in Figure 4, and Figure 6 is a cross-sectional view taken along line VI-VI of the adhesive device shown in Figure 4. Figure 7 shows a cross-sectional view of the adhesive device shown in Figure 2 with the first release sheet, the second release sheet, and the traction sheet removed, and Figure 8 shows a cross-sectional view of a modified example of the adhesive device shown in Figure 2.

[0011] The adhesive device 1 according to the embodiment of the present disclosure comprises a first base sheet 11, a second base sheet 12 arranged overlapping the first base sheet 11 and having one end connected to the first base sheet 11, a drug-containing resin layer 21 provided on the surface of the first base sheet 11 facing the second base sheet 12, a first release sheet 41 arranged overlapping the surface of the first base sheet 11 facing the second base sheet 12 and covering the drug-containing resin layer 21, a moisture-retaining portion 31 provided on the surface of the second base sheet 12 facing the first base sheet 11 and arranged overlapping the drug-containing resin layer 21 in a plan view of the adhesive device 1, a second release sheet 42 arranged overlapping the surface of the second base sheet 12 facing the first base sheet 11 and covering the moisture-retaining portion 31, and a traction sheet 43 arranged between the first release sheet 41 and the second release sheet 42 and connected to the first release sheet 41 and the second release sheet 42. The adhesive device 1 is used by being attached to the skin and can deliver drugs transdermally.

[0012] The adhesive device 1 has a planar direction and a thickness direction z. The planar direction is the direction in which the first base sheet 11 and the second base sheet 12 extend, and the adhesive device 1 has a first direction x and a second direction y in the planar direction. The first direction x and the second direction y extend in the planar direction and are defined as mutually orthogonal directions.

[0013] The adhesive device 1 has a first base sheet 11, a second base sheet 12, a first release sheet 41, a second release sheet 42, and a traction sheet 43 laminated in the thickness direction z. The side of the first base sheet 11 facing the second base sheet 12 and the side of the second base sheet 12 facing the first base sheet 11 are the inside of the adhesive device 1.

[0014] The first base sheet 11 is a sheet on which a drug-containing resin layer 21 is arranged, and the second base sheet 12 is a sheet on which a moisture-retaining portion 31 is arranged. The drug-containing resin layer 21 is provided on the inner surface of the first base sheet 11, that is, on the surface facing the second base sheet 12, and the moisture-retaining portion 31 is provided on the inner surface of the second base sheet 12, that is, on the surface facing the first base sheet 11. Hereinafter, the first base sheet 11 and the second base sheet 12 may be collectively referred to simply as "base sheets 11, 12".

[0015] In a plan view of the adhesive device 1, the second base sheet 12 is positioned overlapping the first base sheet 11, and one end of the second base sheet 12 in either the first direction x or the second direction y is connected to the first base sheet 11. In Figures 1 to 3, one end of the second base sheet 12 in the first direction x is connected to the first base sheet 11, and in Figures 4 to 6, one end of the second base sheet 12 in the second direction y is connected to the first base sheet 11. The first base sheet 11 and the second base sheet 12 can be unfolded into a planar shape from their overlapping state, with the connection portion 13 between the first base sheet 11 and the second base sheet 12 in between.

[0016] The first base sheet 11 and the second base sheet 12 may be different sheets, as shown in Figures 1 to 6. In this case, the first base sheet 11 and the second base sheet 12 are joined to each other at the connection portion 13 between the first base sheet 11 and the second base sheet 12. The joining of the first base sheet 11 and the second base sheet 12 can be done using known joining methods such as adhesive bonding, welding, or crimping.

[0017] As shown in Figure 8, the first base sheet 11 and the second base sheet 12 may be formed on one side and the other side of the fold line 14, respectively, when the first sheet is folded back along the fold line 14. In this case, the fold line 14 of the first sheet becomes the connection point between the first base sheet 11 and the second base sheet 12. When the connection point 13 of the first embodiment is a fold line, it is preferable that the fold line extends in the second direction y, and when the connection point 13 of the second embodiment is a fold line, it is preferable that the fold line extends in the first direction x.

[0018] The first base sheet 11 and the second base sheet 12 may be separable. If the first base sheet 11 and the second base sheet 12 are different sheets, they can be made separable by joining them relatively weakly or intermittently at the connecting portion 13. If the first base sheet 11 and the second base sheet 12 are formed from a single sheet, they can be made separable by forming a fold line 14 from a perforation, for example.

[0019] The materials of the base sheets 11 and 12 are not particularly limited and can be appropriately selected according to the purpose. Examples of base sheets 11 and 12 include resin films formed from polyolefins (e.g., polyethylene, polypropylene), polyesters (e.g., polyethylene terephthalate), polyamides (e.g., nylon 6), polycarbonate, polyvinyl alcohol, ethylene-vinyl alcohol copolymer, polyvinyl chloride, polyvinylidene chloride, polystyrene, cellulose, acrylic resin, etc.; aluminum foil or aluminum film; foamed resin films such as foamed polyethylene film and foamed polypropylene film; and paper such as glassine paper. These may be used individually or in combination. The base sheets 11 and 12 may or may not be stretchable. The first base sheet 11 and the second base sheet 12 may be made of the same material or different materials.

[0020] The shape (planar shape) of the base sheets 11 and 12 is not particularly limited and can include polygons such as squares, hexagons, and octagons, as well as rounded polygons, circles, ellipses, dumbbell shapes, and irregular shapes.

[0021] The thickness of the base sheets 11 and 12 may be, for example, 0.05 mm or more, or 0.1 mm or more, or 3.0 mm or less, 2.0 mm or less, or 1.0 mm or less.

[0022] The drug-containing resin layer 21 is provided on the surface of the first base sheet 11 facing the second base sheet 12. The moisture-retaining portion 31 is provided on the surface of the second base sheet 12 facing the first base sheet 11 and is positioned to overlap with the drug-containing resin layer 21 in a plan view of the adhesive device 1. The surface of the first base sheet 11 facing the second base sheet 12 refers to the side of the main surface of the first base sheet 11 that faces the second base sheet 12, and is the inner surface of the first base sheet 11. The surface of the second base sheet 12 facing the first base sheet 11 refers to the side of the main surface of the second base sheet 12 that faces the first base sheet 11, and is the inner surface of the second base sheet 12.

[0023] The drug-containing resin layer 21 contains at least a drug and a resin. In the drug-containing resin layer 21, it is preferable that the drug is dispersed in the resin. The drug may be uniformly or non-uniformly distributed in the resin. For example, the drug may be distributed in the resin such that areas with high and low drug concentrations are formed.

[0024] Examples of drugs include low molecular weight compounds, peptides, proteins, high molecular weight compounds such as oligonucleotides, antibody drugs, and nucleic acid drugs. The drug compound preferably has an ionizing group, which, as described later, promotes the release of the drug from the drug-containing resin layer 21 and facilitates the penetration of the drug into the skin when the drug-containing resin layer 21 is brought into contact with the moisture-retaining portion 31 to provide moisture to the surface of the drug-containing resin layer 21 and applied to the skin. Examples of ionizing groups include amino groups, carboxyl groups, sulfonic acid groups, and phosphate groups, and these ionizing groups may exist in the form of pharmaceutically acceptable salts. The drug compound also preferably has an aromatic group, which facilitates the presence of the drug in the resin at high concentrations. The aromatic group is more preferably an aromatic hydrocarbon group.

[0025] The drug contained in the drug-containing resin layer 21 is preferably a pharmaceutical product. Examples of drugs include anti-inflammatory and analgesic agents such as acetaminophen, phenacetin, mefenamic acid, diclofenac sodium, flufenamic acid, aspirin, sodium salicylate, methyl salicylate, glycol salicylate, aminopyrine, alclofenac, ibuprofen, naproxen, flurbiprofen, ketoprofen, amfenac sodium, mepirizole, indomethacin, piroxicam, and felbinac; steroidal anti-inflammatory agents such as hydrocortisone, triamcinolone, dexamethasone, and prednisolone; and hydrochloric acid. Vasodilators such as diltiazem, pentaerythritol tetranitrate, isosorbide dinitrate, tarajipil, nicorandil, nitroglycerin, preniramine lactate, morcidomin, amyl nitrite, trazoline hydrochloride, and nifedipine; antiarrhythmic agents such as procainamide hydrochloride, lidocaine hydrochloride, propranolol hydrochloride, alprenolol hydrochloride, atenolol, nadolol, metoprolol tartrate, ajmaline, disopyramide, and mexiletine hydrochloride; ecalazine hydrochloride, indapamide, clonidine hydrochloride, bnitrolol hydrochloride, labetalol hydrochloride, and captopurisine hydrochloride. Antihypertensive agents such as guanabenz acetate, mebutamate, and betanidine sulfate; antihypertensive agents such as carbetapentane citrate, cloperastin, oxerazine tannate, clobutinol hydrochloride, clofedanol hydrochloride, noscapine hydrochloride, ephedrine hydrochloride, isoproterenol hydrochloride, chloriprenaline hydrochloride, methoxyphenamine hydrochloride, procaterol hydrochloride, tulobuterol hydrochloride, clenputerol hydrochloride, and ketotifen fumarate; and antiseptics such as cyclophosphamide, fluorouracil, degafur, mitomycin C, procarbazine hydrochloride, and doxif Antineoplastic agents such as rulizine and ranimustine; local anesthetics such as ethyl aminobenzoate, tetracaine hydrochloride, brocaine hydrochloride, dibucaine hydrochloride, oxybuprocaine hydrochloride, and propitocaine hydrochloride; hormonal agents such as propylthiouracil, thiamazole, meteronone acetate, estradiol, estriol, and progesterone; antihistamines such as diphenhydramine hydrochloride, chlorpheniramine maleate, promethazine, diproheptadine hydrochloride, and diphenylpyraline hydrochloride; anticoagulants such as warfarin potassium and ticlopidine hydrochloride;Antispasmodics such as methylatropine bromide and scopolamine; general anesthetics such as thiopental sodium and pentobarbital sodium; hypnotics and analgesics such as bromwarenylurea, amobarbital, and phenobarbital; antiepileptics such as phenytoin sodium; stimulants and aphrodisiacs such as methamphetamine hydrochloride; sedatives such as difendol hydrochloride and betahistine mesylate; chlorpromazine hydrochloride, thioridazine, meprobamate, imipramine hydrochloride, chlordiazepoxide, diazepam, risperidone, and paliperidone. Psychotropic agents such as olanzapine, aripiprazole, paroxetine, and duloxetine; skeletal muscle relaxants such as succinylcholine hydrochloride and eperisone hydrochloride; autonomic nervous system agents such as neostigmine bromide and bethanechol chloride; antiparkinsonian agents such as amantadine hydrochloride, rotigotine, and ropinirole; anti-Alzheimer's disease drugs such as donepezil, galantamine, memantine, and rivastigmine; diuretics such as hydroflumethiazide, isosorbide, and furosemide; vasoconstrictors such as phenylephrine hydrochloride; loberine bromide, dimol Respiratory stimulants such as holamine and naloxone hydrochloride; peptic ulcer treatments such as glycopyrronium bromide, proglumide, cetraxate hydrochloride, cimetidine, and spizoflon; cholagogues such as ursodeoxycholic acid and osalmid; urogenital and anal preparations such as hexamine, spartin, dinoprost, ritodrine hydrochloride, oxybutynin, tolterodine, solifenacin, and dalifenacin; parasitic skin disease treatments such as salicylic acid, cyclopiroxolamine, and coloconazole hydrochloride; emollients such as urea; calcitriol Vitamin preparations such as thiamine hydrochloride, riboflavin sodium phosphate, pyridoxine hydrochloride, nicotinamide, panthenol, and ascorbic acid; inorganic preparations such as calcium chloride, potassium iodide, and sodium iodide; hemostatic agents such as ethanesylates; liver disease agents such as thiopronin; habitual poisoning agents such as cyanamide; gout treatment agents such as colchicine, probenecid, and sulfinpyrazone; antidiabetic agents such as tolbutamide, chlorpropamide, glimidine sodium, glypsol, buformin hydrochloride, and insulin;Examples include antibiotics such as benzylpenicillin potassium, propicillin potassium, cloxacillin sodium, ampicillin sodium, bacampyricin hydrochloride, carbenicillin sodium, cephalolidine, cefoxitin sodium, erythromycin, chloramphenicol, tetracycline, kanamycin sulfate, and cycloserine; chemocytogenic agents such as isocyanides, pyrazinamide, and ethionamide; and narcotics such as morphine hydrochloride, codeine phosphate, cocaine hydrochloride, pethidine hydrochloride, and fentanyl citrate.

[0026] Examples of resins that form the drug-containing resin layer 21 include fluorine-based resins such as polytetrafluoroethylene (PTFE), acrylic resins such as octyl acrylate copolymers, silicone resins, polyester resins, styrene-based thermoplastic elastomers such as styrene-isoprene-styrene block copolymers, vinyl chloride resins, polyolefin resins, acrylic acid copolymers, polyethylene glycol, vinyl polymers such as polyvinyl alcohol and polyvinylpyrrolidone, and cellulose derivatives.

[0027] The drug-containing resin layer 21 may contain a tackifier. Known tackifiers can be used. The drug-containing resin layer 21 may also contain additives such as plasticizers, drug solvents, permeation enhancers, crystal precipitation inhibitors, excipients, antioxidants, tackifiers, fragrances, colorants, etc.

[0028] The thickness of the drug-containing resin layer 21 may be, for example, 0.01 mm or more, or 0.05 mm or more, or it may be 2.0 mm or less, 1.5 mm or less, or 1.2 mm or less.

[0029] The moisture-retaining portion 31 contains at least moisture. Moisture is retained in the moisture-retaining portion 31, and when the adhesive device 1 is used, the moisture retained in the moisture-retaining portion 31 is attached to the surface of the drug-containing resin layer 21 (specifically, the surface of the drug-containing resin layer 21 opposite to the first base sheet 11). Preferably, the moisture includes at least water such as tap water, purified water, distilled water, sterile purified water, or water for injection. In addition to water, the moisture may also contain additives such as sodium chloride, ethanol, or glycerin. Examples of substances containing sodium chloride in addition to water include saline solution and physiological saline solution, examples of substances containing ethanol in addition to water include disinfectant solutions and antiseptic solutions, and examples of substances containing glycerin in addition to water include cosmetics.

[0030] The moisture-retaining portion 31 may contain only moisture, or it may contain moisture in a moisture-retaining member. It is preferable that the moisture-retaining portion 31 retains moisture so that moisture can be supplied to the surface of the drug-containing resin layer 21 by contacting the drug-containing resin layer 21. Furthermore, it is preferable that moisture is stably retained in the moisture-retaining portion 31 before use of the adhesive device 1. From this viewpoint, it is preferable that the moisture-retaining portion 31 has a porous body that retains moisture or a fiber aggregate that retains moisture.

[0031] The porous material preferably has voids inside, and these voids are in communication with the outside of the porous material. For example, the porous material preferably contains air bubbles, and preferably has continuous air bubbles where the air bubbles are connected. The porous material preferably is elastically deformable, and a sponge is a suitable example of such a porous material, and the porous material is preferably composed of a resin. Examples of resins that constitute the porous material include polyurethane resins, fluororesins such as PTFE, PFA, and ETFE, polyolefin resins such as polyethylene and polypropylene, polyester resins such as polyethylene terephthalate and polybutylene terephthalate, silicone resins such as polydimethylsiloxane, polyamide resins such as nylon, and cellulose derivatives such as hydroxyethylcellulose and hydroxypropylcellulose.

[0032] Examples of fiber aggregates include nonwoven fabrics, woven fabrics, knitted fabrics, and other fabric materials, as well as fiber bundles. Fiber aggregates may also be felt or tow (fiber bundles). Fibers included in the fiber aggregates include natural fibers such as cotton, linen, and silk; regenerated fibers such as rayon; semi-synthetic fibers such as acetate; and synthetic fibers formed from polyester (e.g., PET), polyolefins (e.g., polypropylene, polyethylene), polyurethane, polyamide (e.g., nylon), acrylic, melamine, etc. It is preferable that the surface of the synthetic fibers is hydrophilized with a surfactant or the like. The basis weight of the fiber aggregate is, for example, 200 g / m². ２ Above, 300g / m ２ or more, or 400 g / m ２ It may be greater than or equal to 5000 g / m². ２ Below, 3500g / m ２ The following or 2500 g / m ２ The following is also acceptable.

[0033] The thickness of the moisture-retaining portion 31 may be, for example, 1 mm or more, 2 mm or more, or 10 mm or less, 9 mm or less, or 8 mm or less.

[0034] The first release sheet 41 is positioned overlapping the inner surface of the first base sheet 11, that is, the surface facing the second base sheet 12, and is laminated on the first base sheet 11 so as to cover the drug-containing resin layer 21. The second release sheet 42 is positioned overlapping the inner surface of the second base sheet 12, that is, the surface facing the first base sheet 11, and is laminated on the second base sheet 12 so as to cover the moisture-retaining portion 31. Before use of the adhesive device 1, the drug-containing resin layer 21 is protected by the first release sheet 41, and moisture leakage from the moisture-retaining portion 31 is prevented by the second release sheet 42. Hereinafter, the first release sheet 41 and the second release sheet 42 may be collectively referred to simply as "release sheets 41, 42".

[0035] The material of the release sheets 41 and 42 is not particularly limited and can be appropriately selected depending on the purpose. Examples of release sheets 41 and 42 include paper such as glassine paper; resin films formed from polyolefins (e.g., polyethylene, polypropylene), polyesters (e.g., polyethylene terephthalate), polystyrene, etc.; aluminum foil or aluminum film; and foamed resin films such as foamed polyethylene film and foamed polypropylene film. These may be used individually or in combination. Release sheets 41 and 42 can also be treated with silicone processing, fluororesin processing, embossing, hydrophilic processing, hydrophobic processing, etc.

[0036] The first release sheet 41 is preferably peelably bonded to the first base sheet 11 and / or the drug-containing resin layer 21. In order for the first release sheet 41 to be peelably bonded to the first base sheet 11, it is preferable that an adhesive layer is provided on the first release sheet 41 or the first base sheet 11, or that the first release sheet 41 and the first base sheet 11 are pressed together. The first release sheet 41 and the first base sheet 11 may also be heat-pressed together. In order for the first release sheet 41 to be peelably bonded to the drug-containing resin layer 21, the inner surface of the drug-containing resin layer 21, i.e., the surface opposite to the first base sheet 11, may be adhesive, or an adhesive layer may be provided on the first release sheet 41.

[0037] The second release sheet 42 is preferably peelably bonded to the second base sheet 12. In order for the second release sheet 42 to be peelably bonded to the second base sheet 12, it is preferable that an adhesive layer is provided on the second release sheet 42 or the second base sheet 12, or that the second release sheet 42 and the second base sheet 12 are pressed together. The second release sheet 42 and the second base sheet 12 may also be heat-pressed together. The second release sheet 42 is preferably peelably bonded to the second base sheet 12 so as to surround the moisture-retaining portion 31.

[0038] A traction sheet 43 is positioned between the first release sheet 41 and the second release sheet 42, and the traction sheet 43 is connected to the first release sheet 41 and the second release sheet 42. Specifically, the traction sheet 43 is positioned between the first release sheet 41 and the second release sheet 42, with a portion of the traction sheet 43 overlapping the drug-containing resin layer 21 and the moisture-retaining portion 31 in the first direction x, one end of the traction sheet 43 in the first direction x is connected to the first release sheet 41 and the second release sheet 42, and the other end 43E of the traction sheet 43 in the first direction x is positioned without overlapping the first base sheet 11, the second base sheet 12, the first release sheet 41 and the second release sheet 42. With the traction sheet 43 provided in this manner, the first release sheet 41 and the second release sheet 42 can be pulled out from between the first base sheet 11 and the second base sheet 12 by grasping the other end 43E of the traction sheet 43 and pulling in the first direction x. As a result, the drug-containing resin layer 21, which was covered by the first release sheet 41, is exposed, and the moisture-retaining portion 31, which was covered by the second release sheet 42, is exposed, allowing the drug-containing resin layer 21 to come into contact with the moisture-retaining portion 31, as shown in Figure 7. Consequently, moisture can be applied to the surface of the drug-containing resin layer 21, that is, the surface of the drug-containing resin layer 21 opposite to the first base sheet 11.

[0039] The adhesive device 1 is attached to the skin by first applying moisture to the surface of the drug-containing resin layer 21, then separating the overlapping of the first base sheet 11 and the second base sheet 12, and bringing the drug-containing resin layer 21 into contact with the skin. When the adhesive device 1 is attached in this way, the moisture attached to the drug-containing resin layer 21 adheres to the skin surface, making the skin surface covered by the drug-containing resin layer 21 more susceptible to swelling and softening due to the moisture. This increases the adhesion of the drug-containing resin layer 21 to the skin surface and enhances the penetration of the drug from the drug-containing resin layer 21 into the skin.

[0040] The patch device 1 can easily supply moisture to the surface of the drug-containing resin layer 21 by pulling the pull sheet 43 and pulling out the first release sheet 41 and the second release sheet 42. Therefore, moisture can be supplied to the surface of the drug-containing resin layer 21 through a simple operation, and the patch device 1 can be obtained that is easy to handle.

[0041] For the pull sheet 43, sheets used as the base sheets 11, 12 and the release sheets 41, 42 can be used. One end portion of the pull sheet 43 in the first direction x refers to a portion within a predetermined range from one end of the pull sheet 43 in the first direction x toward the first direction x. It is preferable that at least a part of a region corresponding to one-third of the pull sheet 43 on one side in the first direction x is connected to the first release sheet 41 and the second release sheet 42.

[0042] The other end portion 43E of the pull sheet 43 in the first direction x refers to a portion within a predetermined range from the other end of the pull sheet 43 in the first direction x toward the first direction x. A portion including the other end of the pull sheet 43 in the first direction x is disposed without overlapping the first base sheet 11, the second base sheet 12, the first release sheet 41, and the second release sheet 42 in a plan view of the patch device 1. In the patch device 1, the side where the pull sheet 43 is disposed without overlapping the first base sheet 11, the second base sheet 12, the first release sheet 41, and the second release sheet 42 is defined as the other side of the patch device 1 in the first direction x.

[0043] The traction sheet 43 is positioned so that a portion of it overlaps with the drug-containing resin layer 21 and the moisture-retaining portion 31 in the first direction x. That is, one end of the traction sheet 43 in the first direction x is either positioned to overlap with the drug-containing resin layer 21 and the moisture-retaining portion 31 in the first direction x, or is located on one side of the drug-containing resin layer 21 and the moisture-retaining portion 31 in the first direction x. This makes it easier to smoothly pull out the first release sheet 41 and the second release sheet 42 from between the first base sheet 11 and the second base sheet 12 when the other end 43E of the traction sheet 43 is grasped and pulled to the other side in the first direction x. For example, even if the first release sheet 41 is detachably bonded to the first base sheet 11 or the drug-containing resin layer 21, or if the second release sheet 42 is detachably bonded to the second base sheet 12, the first release sheet 41 can be smoothly peeled off from the first base sheet 11 or the drug-containing resin layer 21, and the second release sheet 42 can be smoothly peeled off from the second base sheet 12. Preferably, one end of the traction sheet 43 in the first direction x is located on one side of the first direction x than the drug-containing resin layer 21 and the moisture-retaining portion 31. That is, it is preferable that the traction sheet 43 is arranged to overlap with the drug-containing resin layer 21 and the moisture-retaining portion 31 in the first direction x, and extends on both the one side and the other side of the first direction x than the drug-containing resin layer 21 and the moisture-retaining portion 31.

[0044] The traction sheet 43 does not need to overlap with the drug-containing resin layer 21 and the moisture-retaining portion 31 in a plan view of the attachment device 1, as long as a portion of it overlaps with the drug-containing resin layer 21 and the moisture-retaining portion 31 in a first direction x. For example, the traction sheet 43 may not overlap with the drug-containing resin layer 21 and the moisture-retaining portion 31 in a plan view of the attachment device 1, but may be located on both sides of the drug-containing resin layer 21 and the moisture-retaining portion 31 in a second direction y, and may be arranged to overlap with the drug-containing resin layer 21 and the moisture-retaining portion 31 in a first direction x.

[0045] The length in the first direction x of the other end 43E in the first direction x, where the pull sheet 43 is arranged without overlapping the first base sheet 11, the second base sheet 12, the first release sheet 41, and the second release sheet 42, may be 5 mm or more, 7 mm or more, or 10 mm or more, and may be 100 mm or less, 75 mm or less, or 50 mm or less. This makes it easy to grip the other end 43E of the pull sheet 43 in the first direction x, and improves the handleability of the application device 1.

[0046] The first release sheet 41, the second release sheet 42, and the pull sheet 43 may be separate sheets from each other, as shown in FIGS. 1 to 6. In this case, the first release sheet 41, the second release sheet 42, and the pull sheet 43 are joined to each other at a connecting portion 44. For joining the first release sheet 41, the second release sheet 42, and the pull sheet 43, known joining means such as adhesion, welding, and pressure bonding can be used.

[0047] As shown in FIG. 8, for the first release sheet 41, the second release sheet 42, and the pull sheet 43, two or more of the first release sheet 41, the second release sheet 42, and the pull sheet 43 may be formed from a single sheet. In FIG. 8, the first release sheet 41 and the second release sheet 42 are formed from a single sheet. In this case, for example, the first base sheet 11 and the second base sheet 12, the first release sheet 41 and the pull sheet 43, or the second release sheet 42 and the pull sheet 43 can be respectively formed on one side and the other side across a fold line by folding a single sheet along the fold line. The fold line of the single sheet serves as a connecting portion between the first base sheet 11 and the second base sheet 12, a connecting portion between the first release sheet 41 and the pull sheet 43, or a connecting portion between the second release sheet 42 and the pull sheet 43. It is preferable that the fold line extends in the second direction y. In FIG. 8, a single sheet is folded along a fold line 45, and the first release sheet 41 and the second release sheet 42 are respectively formed on one side and the other side across the fold line 45.

[0048] The first release sheet 41, the second release sheet 42, and the traction sheet 43 may be formed from a single sheet. In this case, the single sheet can be folded in an accordion shape along a first fold line, a second fold line, and a third fold line, each extending in the second direction y. The portion of the sheet on one side from the first fold line (opposite the second fold line from the first fold line) can be made into the first release sheet 41, the portion between the first and third fold lines into the traction sheet 43, and the portion on the other side from the third fold line (opposite the second fold line from the third fold line) into the second release sheet 42.

[0049] The inner surface of the drug-containing resin layer 21, that is, the surface opposite to the first base sheet 11, is preferably adhesive. For the inner surface of the drug-containing resin layer 21, that is, the surface opposite to the first base sheet 11, to be adhesive, it is preferable that the resin contained in the drug-containing resin layer 21 is an elastomer resin. This makes it possible to improve the adhesion and conformability of the drug-containing resin layer 21 to the skin when the adhesive device 1 is attached to the skin, and makes it easier to transfer the drug from the drug-containing resin layer 21 to the skin surface.

[0050] The adhesive device 1, in which the side of the drug-containing resin layer 21 opposite to the first base sheet 11 is adhesive, allows, for example, the drug-containing resin layer 21 to be peeled off the first base sheet 11 and attached to the skin. In this case, as shown in Figure 9, it is preferable that a support layer 22 is provided on the side of the drug-containing resin layer 21 that is on the first base sheet 11 side, and that the support layer 22 is detachably attached to the first base sheet 11. Figure 9 shows a cross-sectional view of another embodiment of the adhesive device 1, and shows an example in which a support layer 22 is provided to the adhesive device 1 shown in Figure 2. The support layer 22 is handled integrally with the drug-containing resin layer 21. The traction sheet 43 is pulled to the other side in the first direction x, the first release sheet 41 and the second release sheet 42 are pulled out from between the first base sheet 11 and the second base sheet 12, and after the overlap of the first base sheet 11 with the second base sheet 12 is released, the drug-containing resin layer 21 can be peeled off from the first base sheet 11 together with the support layer 22, thereby allowing the drug-containing resin layer 21 to be attached to the skin.

[0051] The type of support layer 22 is not particularly limited, and known types can be used. Examples of support layers 22 include stretchable or non-stretchable woven or nonwoven fabrics formed from polyethylene, polypropylene, polyester, etc.; films formed from polyethylene, polypropylene, ethylene vinyl acetate copolymer, vinyl chloride, polyurethane, etc.; and foamed supports formed from polyethylene, polyurethane, etc. These may be used individually or in combination. The support layer 22 may also be a nonwoven or woven fabric containing an antistatic agent to prevent static electricity buildup and to ensure good anchoring with the drug-containing resin layer 21. The support layer 22 may also be a material that has been subjected to a release process (e.g., silicone processing).

[0052] When the support layer 22 is peelably attached to the first base sheet 11, it is preferable that the first base sheet 11 has an adhesive portion that overlaps with the support layer 22. This allows the support layer 22 to be peelably attached to the first base sheet 11. In this case, the adhesive portion does not need to be provided in the area of ​​the first base sheet 11 where the support layer 22 is not placed, thereby making it easier to peel the support layer 22 from the first base sheet 11. The adhesive portion may be provided over the entire area of ​​the first base sheet 11 where the support layer 22 is placed, or only in a part of it. From the viewpoint of making it easier to peel the support layer 22 from the first base sheet 11, it is preferable that, in a plan view of the attachment device 1, at least a part of the outer edge of the adhesive portion is located inward from the outer edge of the support layer 22, and it is more preferable that the entire outer edge of the adhesive portion is located inward from the outer edge of the support layer 22.

[0053] The adhesive device 1 may be used by attaching the drug-containing resin layer 21 to the skin together with the first base sheet 11. In this case, it is preferable that an adhesive portion is provided around the drug-containing resin layer 21 of the first base sheet 11. This allows the first base sheet 11 to adhere to the skin so as to surround the drug-containing resin layer 21 when the adhesive device 1 is attached to the skin, and the skin surface on which the drug-containing resin layer 21 is placed becomes more susceptible to softening due to moisture. In other words, moisture is supplied to the surface of the drug-containing resin layer 21 from the moisture-retaining portion 31, and furthermore, the moisture supplied from the surface of the drug-containing resin layer 21 to the skin surface tends to remain between the drug-containing resin layer 21 and the skin without escaping from the first base sheet 11, making the skin surface covered by the drug-containing resin layer 21 more susceptible to softening.

[0054] In the above case, a support layer 22 is not required on the side of the drug-containing resin layer 21 that faces the first base sheet 11. The inner surface of the drug-containing resin layer 21, that is, the surface of the drug-containing resin layer 21 opposite to the first base sheet 11, may or may not be adhesive, but from the viewpoint of improving the adhesion of the drug-containing resin layer 21 to the skin, it is preferable that the surface of the drug-containing resin layer 21 opposite to the first base sheet 11 is adhesive.

[0055] If the adhesive device 1 is used by attaching a drug-containing resin layer 21 to the skin together with a first base sheet 11, it is preferable that the first base sheet 11 and the second base sheet 12 are separable. This allows the first base sheet 11 to be separated from the second base sheet 12, and the drug-containing resin layer 21 to be attached to the skin together with the first base sheet 11.

[0056] Even if the adhesive device 1 is used by peeling the drug-containing resin layer 21 from the first base sheet 11 and attaching it to the skin, that is, if a support layer 22 is provided on the first base sheet 11 side of the drug-containing resin layer 21 and the support layer 22 is detachably attached to the first base sheet 11, the first base sheet 11 may be separable from the second base sheet 12. The adhesive device 1 configured in this way can be used by separating the first base sheet 11 from the second base sheet 12, placing the drug-containing resin layer 21 on the skin together with the first base sheet 11 and attaching the drug-containing resin layer 21 to the skin, and then peeling the first base sheet 11 from the support layer 22. This allows the adhesive device 1 to be attached to the skin without touching the drug-containing resin layer 21.

[0057] Preferably, the drug-containing resin layer 21 is provided protruding from the inner surface of the first base sheet 11. This makes it easier to peel the drug-containing resin layer 21 from the first base sheet 11 together with the support layer 22 when peeling the drug-containing resin layer 21 from the first base sheet 11 and applying it to the skin. When applying the drug-containing resin layer 21 to the skin together with the first base sheet 11, it is easier to improve the adhesion of the drug-containing resin layer 21 to the skin.

[0058] In one embodiment of the adhesive device 1, it is preferable that the size of the drug-containing resin layer 21 is smaller than the size of the moisture-retaining portion 31. Specifically, in a plan view of the adhesive device 1, it is preferable that the size of the drug-containing resin layer 21 is smaller than the size of the moisture-retaining portion 31. This makes it easier to bring the entire inner surface of the drug-containing resin layer 21, i.e., the surface opposite to the first base sheet 11, into contact with the moisture-retaining portion 31 when the traction sheet 43 is pulled to remove the first release sheet 41 and the second release sheet 42, and makes it easier to adhere moisture to a wide area of ​​the drug-containing resin layer 21.

[0059] The moisture-retaining portion 31 is preferably provided in a recessed portion on the inner surface of the second base sheet 12. That is, it is preferable that a recess 15 is provided on the surface of the second base sheet 12 facing the first base sheet 11, and the moisture-retaining portion 31 is placed in the recess 15. By placing the moisture-retaining portion 31 in the recess 15 of the second base sheet 12, moisture can be stably retained in the moisture-retaining portion 31. If the moisture-retaining portion 31 is a porous material or a fiber aggregate in which moisture is retained, it is prevented that the moisture-retaining portion 31 is inadvertently pressed before use of the adhesive device 1, and moisture is stably retained in the porous material or fiber aggregate.

[0060] It is preferable that the size of the drug-containing resin layer 21 is smaller than the size of the recess 15. Specifically, in a plan view of the adhesive device 1, it is preferable that the size of the drug-containing resin layer 21 is smaller than the size of the recess 15. This makes it easier to insert the entire drug-containing resin layer 21 into the recess 15 when the traction sheet 43 is pulled to remove the first release sheet 41 and the second release sheet 42, and makes it easier to attach more moisture to the drug-containing resin layer 21.

[0061] When a support layer 22 is provided on the first base sheet 11 side of the drug-containing resin layer 21, and the support layer 22 is peelably attached to the first base sheet 11, as shown in Figure 10, a temporary fixing portion 51 of the drug-containing resin layer 21 may be provided around at least a part of the moisture-retaining portion 31 of the second base sheet 12. Figure 10 shows a cross-sectional view of another embodiment of the adhesive device 1, which shows an example in which a temporary fixing portion 51 is provided around the moisture-retaining portion 31 of the second base sheet 12 in the adhesive device 1 shown in Figure 2.

[0062] The temporary fastening portion 51 is configured so that when the traction sheet 43 is pulled to remove the first release sheet 41 and the second release sheet 42 and the drug-containing resin layer 21 is placed on the moisture-retaining portion 31, the portion of the drug-containing resin layer 21 that protrudes from the moisture-retaining portion 31 can be temporarily fastened to the second base sheet 12. By temporarily fastening a portion of the drug-containing resin layer 21 to the second base sheet 12, and then releasing the overlap between the first base sheet 11 and the second base sheet 12, the drug-containing resin layer 21 can be peeled off the first base sheet 11. After that, by peeling the drug-containing resin layer 21 from the temporary fastening portion 51 of the second base sheet 12, the drug-containing resin layer 21 can be removed with moisture still attached to its surface and applied to the skin. In this case, it is preferable that the size of the drug-containing resin layer 21 is larger than the size of the moisture-retaining portion 31.

[0063] The temporary fixing portion 51 has a peel adhesive strength when bonded to the drug-containing resin layer 21 that is greater than the peel adhesive strength between the support layer 22 and the first base sheet 11, and less than the peel adhesive strength between the support layer 22 and the drug-containing resin layer 21. The peel adhesive strength is determined by a 90-degree peel test. The temporary fixing portion 51 can be formed, for example, by providing an adhesive portion around at least a part of the moisture-retaining portion 31 of the second base sheet 12, by providing a sheet material different from the second base sheet 12, or by surface treating at least a part of the moisture-retaining portion 31 of the second base sheet 12.

[0064] When a support layer 22 is provided on the first base sheet 11 side of the drug-containing resin layer 21, and the support layer 22 is peelably attached to the first base sheet 11, and the moisture-retaining portion 31 is provided in a recess 15 on the inner surface of the second base sheet 12, it is also preferable that the temporary fixing portion 51 be provided around at least a part of the moisture-retaining portion 31 in the recess 15 on the inner surface of the second base sheet 12, as shown in Figure 11. Figure 11 shows a cross-sectional view of another embodiment of the adhesive device 1, and shows an example in which the temporary fixing portion 51 is provided around the moisture-retaining portion 31 in the recess 15 of the second base sheet 12 in the adhesive device 1 shown in Figure 2.

[0065] In this case, when the traction sheet 43 is pulled to remove the first release sheet 41 and the second release sheet 42 and the drug-containing resin layer 21 is placed on top of the moisture-retaining part 31, a portion of the drug-containing resin layer 21 can be temporarily fixed to the temporary fixing part 51 provided in the recess 15. Subsequently, by releasing the overlap between the first base sheet 11 and the second base sheet 12 and separating the first base sheet 11 from the second base sheet 12, the drug-containing resin layer 21 can be peeled off the first base sheet 11. Furthermore, by peeling the drug-containing resin layer 21 from the temporary fixing part 51 provided in the recess 15, the drug-containing resin layer 21 can be removed with moisture attached to its surface and applied to the skin.

[0066] When a temporary fastening portion 51 is provided in a recess 15 of the second base sheet 12, it is preferable that the upper surface of the temporary fastening portion 51 is located at a position lower than the upper surface of the moisture-retaining portion 31 by at least half the thickness of the moisture-retaining portion 31. In the recess 15, the bottom side of the recess 15 is defined as the lower side, and the opening side of the recess 15 is defined as the upper side. In the recess 15 provided on the surface of the second base sheet 12 facing the first base sheet 11, the upper surfaces of the temporary fastening portion 51 and the moisture-retaining portion 31 are the surfaces facing the first base sheet 11. The fact that the upper surface of the temporary fastening portion 51 is located at a position lower than the upper surface of the moisture-retaining portion 31 by at least half the thickness of the moisture-retaining portion 31 means that, when the lower surface of the moisture-retaining portion 31 is defined as 0% and the upper surface of the moisture-retaining portion 31 as 100% in the thickness direction z of the adhesive device 1, the upper surface of the temporary fastening portion 51 is located at a position of 50% or more but less than 100% in the thickness direction z of the moisture-retaining portion 31. This makes it easier for the moisture held in the moisture-retaining portion 31 to adhere to the upper surface of the drug-containing resin layer 21 when the drug-containing resin layer 21 is placed on top of the moisture-retaining portion 31 located in the recess 15, and also makes it easier to temporarily fix the upper surface of the drug-containing resin layer 21 to the temporary fixing portion 51. The upper surface of the temporary fixing portion 51 may be located at a position lower than 1 / 3 or less of the thickness of the moisture-retaining portion 31 than the upper surface of the moisture-retaining portion 31, at a position lower than 1 / 4 or less of the thickness of the moisture-retaining portion 31, at a position lower than 1 / 20 or more of the thickness of the moisture-retaining portion 31, or at a position lower than 1 / 10 or more of the thickness of the moisture-retaining portion 31. In other words, the upper surface of the temporary fixing portion 51 may be located at a position between 67% and 95% of the thickness direction z of the moisture-retaining portion 31, or at a position between 75% and 90%.

[0067] As described above, since the upper surface of the temporary fastening portion 51 is formed at a certain height from the lower surface of the moisture-retaining portion 31, it is preferable that a base portion 52 is provided in the recess 15 of the second base sheet 12 in at least a part of the periphery of the moisture-retaining portion 31, and that the temporary fastening portion 51 is provided on the upper surface of the base portion 52. The temporary fastening portion 51 on the upper surface of the base portion 52 may be formed by appropriately selecting the constituent material of the base portion 52 itself to function as a temporary fastening portion 51, or a sheet material that functions as a temporary fastening portion 51 may be provided on the upper surface of the base portion 52, or the temporary fastening portion 51 may be formed by surface treatment of the upper surface of the base portion 52.

[0068] When the traction sheet 43 is pulled to remove the first release sheet 41 and the second release sheet 42 and the drug-containing resin layer 21 is placed on top of the moisture-retaining portion 31, it is preferable that the first base sheet 11 has a pressing portion 16 that can be pressed towards the second base sheet 12, and that the drug-containing resin layer 21 is placed on the pressing portion 16. With the first base sheet 11 configured in this way, as shown in Figure 7, when the drug-containing resin layer 21 is placed on top of the moisture-retaining portion 31, the pressing portion 16 can be pressed from the side opposite to the second base sheet 12, thereby strongly pressing the drug-containing resin layer 21 against the moisture-retaining portion 31. This makes it easier to adhere more moisture to the surface of the drug-containing resin layer 21.

[0069] The indentation portion 16 can be formed, for example, from a bulge formed by the first base sheet 11 bulging toward the opposite side of the second base sheet 12, and deformable into a shape that bulges toward the second base sheet 12. In this case, by pressing the indentation portion 16 from the opposite side of the second base sheet 12, the bulge formed by bulging toward the opposite side of the second base sheet 12 can be deformed into a shape that bulges toward the second base sheet 12, and the first base sheet 11 can be pressed toward the second base sheet 12 in the indentation portion 16. Although not shown in the drawings, the indentation portion 16 may also be formed by folding the first base sheet 11. The folded portion of the first base sheet 11 becomes movable in the thickness direction z, and the indentation portion 16 can be formed.

[0070] Preferably, the surface of the drug-containing resin layer 21, that is, the surface opposite to the first base sheet 11, has a hydrophobic region. If a hydrophobic region is formed on the surface of the drug-containing resin layer 21 opposite to the first base sheet 11, it becomes easier to release the drug from the drug-containing resin layer 21 by applying water to the surface of the drug-containing resin layer 21 and attaching the adhesive device 1 to the skin. For example, if the entire surface of the drug-containing resin layer 21 opposite to the first base sheet 11 is a hydrophilic region, even if moisture is applied to the drug-containing resin layer 21, the drug will not be sufficiently distributed to the moisture and will tend to remain in the drug-containing resin layer 21. However, if the surface of the drug-containing resin layer 21 opposite to the first base sheet 11 has a hydrophobic region, the drug contained in the drug-containing resin layer 21 will easily migrate from the drug-containing resin layer 21 to the moisture attached to the surface. The drug released from the drug-containing resin layer 21 will easily penetrate the skin along with the moisture without returning to the drug-containing resin layer 21.

[0071] The hydrophobic region preferably has a water contact angle of 80° or higher as determined by a wettability test. This ensures hydrophobicity in the hydrophobic region. The water contact angle of the hydrophobic region may be 85° or higher, 90° or higher, 95° or higher, 100° or higher, or 102° or higher. There is no particular upper limit to the water contact angle of the hydrophobic region, but it is preferably 120° or lower, which makes it easier for moisture to adhere to the surface of the drug-containing resin layer 21. The water contact angle of the hydrophobic region may be 118° or lower, 115° or lower, or 110° or lower.

[0072] The water contact angle obtained by the wettability test can be measured in accordance with JIS R 3257:1999, and can be measured using a contact angle measuring instrument such as the Mobile Drop DSA series manufactured by Krus. Distilled water is dropped onto the surface of the drug-containing resin layer 21 from the microsyringe of the contact angle measuring instrument, and the angle between the surface of the drug-containing resin layer 21 and the water droplet is read one minute after dropping. The angle can be read by analyzing images captured by a camera such as a high-resolution CCD camera using analysis software.

[0073] The surface of the drug-containing resin layer 21 opposite the first base sheet 11 may be entirely hydrophobic, or it may have a hydrophilic region in part. Preferably, a wide area of ​​the surface of the drug-containing resin layer 21 opposite the first base sheet 11 is hydrophobic. For example, it is preferable that 50% or more of the surface of the drug-containing resin layer 21 opposite the first base sheet 11 is hydrophobic, and it may be 70% or more, 80% or more, or 90% or more. On the surface of the drug-containing resin layer 21 opposite the first base sheet 11, the area other than the hydrophobic region can be called the hydrophilic region. The water contact angle in the hydrophilic region is preferably less than 80°, and may be 75° or less, 70° or less, 60° or less, 50° or less, or 40° or less. If the surface of the drug-containing resin layer 21 opposite the first base sheet 11 has both a hydrophobic region and a hydrophilic region, it is preferable to cut out each region and measure the water contact angle.

[0074] This disclosure also provides an adhesive device package in which the above-mentioned adhesive device 1 is enclosed in a packaging bag. An example of the configuration of an adhesive device package according to an embodiment of this disclosure will be described with reference to Figure 12. Figure 12 shows a plan view of the adhesive device package.

[0075] The adhesive device packaging 61 according to the embodiment of the present disclosure comprises the adhesive device 1 of the present disclosure and a packaging bag 62 in which the adhesive device 1 is enclosed. The packaging bag 62 has an opening portion 63, and by opening it from the opening portion 63, an outlet for the adhesive device 1 is formed on the other end 43E side in the first direction x of the traction sheet 43.

[0076] The packaging bag 62 is not particularly limited as long as it can accommodate the adhesive device 1. The material of the packaging bag 62 can be appropriately selected depending on the purpose, and for example, resin films made from polyester (e.g., polyethylene terephthalate), polyolefin (e.g., polyethylene, polypropylene, cyclic polyolefin copolymer), polyvinyl alcohol, ethylene-vinyl alcohol copolymer, etc., can be used; aluminum foil or aluminum film can be used. These may be used individually or in combination. The packaging bag 62 may be formed, for example, by overlapping two sheet materials and sealing the edges, or by folding one sheet material to make two layers and sealing the edges other than the fold.

[0077] The packaging bag 62 has an opening section 63. The opening section 63 is the part of the packaging bag 62 that is opened in order to remove the adhesive device 1. In Figure 12, a notch is formed on the edge of the packaging bag 62 as the opening section 63. In addition to the above, the opening section 63 can also be formed by making a cut in the edge of the opening bag, forming a flap by providing a non-jointed portion of the sheet material forming the opening bag on a part of the edge of the opening bag, or by making perforations in the packaging bag 62. By cutting the packaging bag 62 starting from the cut or notch, an opening for removing the adhesive device 1 can be formed in the packaging bag 62. By releasing the joint between the sheet materials of the opening bag starting from the flap, an opening for removing the adhesive device 1 can be formed in the packaging bag 62. By cutting the packaging bag 62 along the perforations, an opening for removing the adhesive device 1 can be formed in the packaging bag 62.

[0078] The packaging bag 62 has an opening for the adhesive device 1 on the other end 43E side of the traction sheet 43 in the first direction x. This makes it easier to grasp the other end 43E of the traction sheet 43 in the first direction x when the packaging bag 62 is opened from the opening 63. Therefore, by opening the packaging bag 62 and pulling the other end 43E of the traction sheet 43 in the first direction x, the first release sheet 41 and the second release sheet 42 can be easily pulled out from the adhesive device 1. For example, the first release sheet 41 and the second release sheet 42 can be pulled out by pulling the other end 43E of the traction sheet 43 in the first direction x while the adhesive device 1 is still inside the packaging bag 62. This allows the leaked moisture to be contained within the packaging bag 62 even if moisture leaks from the moisture retention section 31, improving the handling of the adhesive device 1.

[0079] The adhesive device 1 can be used by placing it on epithelial tissue. The epithelial tissue on which the adhesive device 1 is placed may be epithelial tissue of the skin or epithelial tissue of the mucous membrane, but it is preferable that it be epithelial tissue of the skin. The adhesive device 1 is preferably placed on human epithelial tissue, but it may also be placed on the epithelial tissue of animals other than humans, such as dogs, cats, horses, and cattle.

[0080] Although various embodiments of the adhesive device and adhesive device packaging described above have been explained, each component of the adhesive device and adhesive device packaging described above can be implemented by arbitrarily combining or substituting multiple embodiments. For example, the components relating to the support layer, temporary fastening portion, and pressing portion can be applied to any of the embodiments described above.

[0081] This application claims the benefit of priority based on Japanese Patent Application No. 2025-052033, filed on 26 March 2025. The entire specification of Japanese Patent Application No. 2025-052033, filed on 26 March 2025, is incorporated herein by reference.

[0082] 1: Adhesive device 11: First base sheet 12: Second base sheet 13: Connection part 14: Fold line 15: Recess 16: Press-in part 21: Drug-containing resin layer 22: Support layer 31: Moisture-retaining part 41: First release sheet 42: Second release sheet 43: Traction sheet 44: Connection part 45: Fold line 51: Temporary fastening part 52: Base part 61: Adhesive device packaging 62: Packaging bag 63: Opening part x: First direction, y: Second direction, z: Thickness direction

Claims

1. An adhesive device having a first direction and a second direction in a planar direction, comprising: a first base sheet; a second base sheet disposed overlapping the first base sheet and having one end in the first or second direction connected to the first base sheet; a drug-containing resin layer provided on the surface of the first base sheet facing the second base sheet; a first release sheet disposed overlapping the surface of the first base sheet facing the second base sheet and covering the drug-containing resin layer; a moisture-retaining portion provided on the surface of the second base sheet facing the first base sheet and disposed overlapping the drug-containing resin layer in a plan view of the adhesive device; and a second release sheet disposed overlapping the surface of the second base sheet facing the first base sheet and covering the moisture-retaining portion. An adhesive device comprising a traction sheet disposed between the first release sheet and the second release sheet, with a portion of it overlapping the drug-containing resin layer and the moisture-retaining portion in the first direction, wherein one end in the first direction is connected to the first release sheet and the second release sheet, and the other end in the first direction is a traction sheet that is disposed without overlapping the first base sheet, the second base sheet, the first release sheet and the second release sheet.

2. The adhesive device according to claim 1, wherein the first base sheet and the second base sheet are formed on one side and the other side of the fold line, respectively, when the first sheet is folded back along the fold line.

3. The adhesive device according to claim 1, wherein the first release sheet and the second release sheet, the first release sheet and the traction sheet, or the second release sheet and the traction sheet are formed on one side and the other side of the fold line, respectively, when one sheet is folded back along the fold line.

4. The adhesive device according to claim 1, wherein the side of the drug-containing resin layer opposite to the first base sheet is adhesive.

5. The adhesive device according to claim 1, wherein the surface of the drug-containing resin layer opposite to the first substrate sheet has a hydrophobic region.

6. The adhesive device according to claim 1, wherein the first substrate sheet and the second substrate sheet are separable.

7. The adhesive device according to claim 1, wherein a support layer is provided on the first substrate sheet side of the drug-containing resin layer, and the support layer is peelably attached to the first substrate sheet.

8. The adhesive device according to claim 7, wherein the second base sheet has a temporary fixing portion of the drug-containing resin layer provided around at least a portion of the moisture-retaining portion.

9. The adhesive device according to claim 1, wherein a recess is provided on the surface of the second base sheet facing the first base sheet, and the moisture-retaining portion is arranged in the recess.

10. The adhesive device according to claim 9, wherein the size of the drug-containing resin layer is smaller than the size of the moisture-retaining portion.

11. The adhesive device according to claim 1, wherein a recess is provided on the surface of the second base sheet facing the first base sheet, the moisture-retaining portion and a temporary fixing portion of the drug-containing resin layer are provided in the recess, and the upper surface of the temporary fixing portion is located at a position lower than or equal to half the thickness of the moisture-retaining portion than the upper surface of the moisture-retaining portion.

12. The adhesive device according to any one of claims 9 to 11, wherein the first base sheet has a pressable portion formed therein that can be pressed into the second base sheet, and the drug-containing resin layer is disposed in the pressable portion.

13. The adhesive device according to claim 1, wherein the moisture-retaining portion is a porous body that retains moisture or a fiber aggregate that retains moisture.

14. An adhesive device packaging comprising an adhesive device according to any one of claims 1 to 11 or 13, and a packaging bag containing the adhesive device, wherein the packaging bag has an opening portion, and by opening from the opening portion, an outlet for the adhesive device is formed on the other end side of the traction sheet in the first direction.

Images